1. Volume 64, Pages e1-e3 (January 2017)
Immunotherapy in head and neck cancer: Need for a new strategy? Rapid progression with nivolumab then unexpected response with next treatment 
Amaury Daste 
Oral Oncology 
Volume 64, Pages e1-e3 (January 2017)
DOI: /j.oraloncology
Copyright © 2016 Elsevier Ltd Terms and Conditions

2. Fig. 1
Oral cavity and lung cancers at baseline (A) and after 6 cycles of nivolumab (B).
Oral Oncology  , e1-e3DOI: ( /j.oraloncology )
Copyright © 2016 Elsevier Ltd Terms and Conditions

3. Fig. 2
Oral cavity and lung cancers after 11 cycles of nivolumab (A), after 2 cycles of third-line chemotherapy (B) and 3months after the last dose (C).
Oral Oncology  , e1-e3DOI: ( /j.oraloncology )
Copyright © 2016 Elsevier Ltd Terms and Conditions